Arnold L. Oronsky

4.6k total citations · 1 hit paper
114 papers, 3.5k citations indexed

About

Arnold L. Oronsky is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Arnold L. Oronsky has authored 114 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 29 papers in Oncology and 22 papers in Immunology. Recurrent topics in Arnold L. Oronsky's work include Cell Adhesion Molecules Research (16 papers), Osteoarthritis Treatment and Mechanisms (12 papers) and Lung Cancer Research Studies (9 papers). Arnold L. Oronsky is often cited by papers focused on Cell Adhesion Molecules Research (16 papers), Osteoarthritis Treatment and Mechanisms (12 papers) and Lung Cancer Research Studies (9 papers). Arnold L. Oronsky collaborates with scholars based in United States, China and South Africa. Arnold L. Oronsky's co-authors include S.S. Kerwar, Bryan Oronsky, Tony R. Reid, R. J. Perper, Susan C. Ridge, Corey A. Carter, Christopher Larson, Michelle Lybeck, Rama Rajaram and Susan J. Knox and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Arnold L. Oronsky

110 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Review of Persistent Post-COVID Syndrome (PPCS)

2021 269 citations Bryan Oronsky, Christopher Larson et al. profile →

Peers

Countries citing papers authored by Arnold L. Oronsky

Since Specialization

Citations

This map shows the geographic impact of Arnold L. Oronsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnold L. Oronsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnold L. Oronsky more than expected).

Fields of papers citing papers by Arnold L. Oronsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnold L. Oronsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnold L. Oronsky. The network helps show where Arnold L. Oronsky may publish in the future.

Co-authorship network of co-authors of Arnold L. Oronsky

This figure shows the co-authorship network connecting the top 25 collaborators of Arnold L. Oronsky. A scholar is included among the top collaborators of Arnold L. Oronsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnold L. Oronsky. Arnold L. Oronsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	REPLATINUM Phase III Randomized Study: RRx-001 + Platinum Doublet Versus Platinum Doublet in Third-Line Small Cell Lung Cancer 2019 ·Future Oncology ·Bryan Oronsky, Tony R. Reid, Christopher Larson, Scott Caroen, Mary Quinn, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Arnold L. Oronsky, Curtis L. Scribner, Corey A. Carter	47
2	What's New in SCLC? A Review 2017 ·Neoplasia ·Bryan Oronsky, Tony R. Reid, Arnold L. Oronsky, Corey A. Carter	137
3	RRx-001 protects against cisplatin-induced toxicities 2017 ·Journal of Cancer Research and Clinical Oncology ·Bryan Oronsky, Tony R. Reid, Christopher Larson, Corey A. Carter, Christina Brzezniak, Arnold L. Oronsky, Pedro Cabrales	19
4	Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management 2017 ·Cancer Chemotherapy and Pharmacology ·Bryan Oronsky, Scott Caroen, Arnold L. Oronsky, (unknown), Neil Oronsky, Michelle Lybeck, Tony R. Reid, Corey A. Carter	72
5	Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review 2017 ·Neoplasia ·Bryan Oronsky, (unknown), Tony R. Reid, Pedro Cabrales, Michelle Lybeck, Arnold L. Oronsky, Neil Oronsky, Corey A. Carter	22
6	Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation 2016 ·Medical Oncology ·Marcel H.A.M. Fens, Pedro Cabrales, Jan Scicinski, Sandra Larkin, Jung H. Suh, Frans A. Kuypers, Neil Oronsky, Michelle Lybeck, Arnold L. Oronsky, Bryan Oronsky	10
7	Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial 2016 ·Translational Oncology ·Michelle M. Kim, Hemant Parmar, Yue Cao, (unknown), Matthew J. Schipper, James A. Hayman, Larry Junck, Aaron Mammoser, Jason Heth, Corey A. Carter, Arnold L. Oronsky, Susan J. Knox, Scott Caroen, Bryan Oronsky, Jan Scicinski, Theodore S. Lawrence, Christopher D. Lao	27
8	Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies 2016 ·Oncotarget ·Corey A. Carter, (unknown), Regina M. Day, Patrick Richard, Arnold L. Oronsky, Neil Oronsky, Michelle Lybeck, Jan Scicinski, Bryan Oronsky	6
9	Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor 2015 ·Case Reports in Oncology ·Corey A. Carter, (unknown), Bryan Oronsky, Jan Scicinski, Scott Caroen, Arnold L. Oronsky, Tony Reid, Pedro Cabrales, (unknown)	11
10	Episensitization: Defying Timeâ€™s Arrow 2015 ·Frontiers in Oncology ·Bryan Oronsky, Arnold L. Oronsky, Michelle Lybeck, Neil Oronsky, Jan Scicinski, Corey Carter, Regina M. Day, (unknown), M. Rodríguez‐Torres, (unknown), Tony R. Reid	32
11	Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study 2015 ·The Lancet Oncology ·Tony Reid, Bryan Oronsky, Jan Scicinski, (unknown), Susan J. Knox, Shoucheng Ning, Donna M. Peehl, Ron Korn, (unknown), Corey A. Carter, Arnold L. Oronsky, Michael J. Taylor, William L. Fitch, Pedro Cabrales, Michelle M. Kim, Howard A. Burris, Christopher D. Lao, (unknown), Gary R. Fanger, Jeffrey R. Infante	76
12	Dysphonia after Bevacizumab Rechallenge: A Case Report 2015 ·Case Reports in Oncology ·Corey A. Carter, Scott Caroen, Arnold L. Oronsky, Bryan Oronsky	7
13	Studies on the effect of CL 306,293, a substituted quinoline car☐ylic acid, on the clinical disease induced in mice with LP-BM5 virus 1993 ·Antiviral Research ·(unknown), Susan Quinn DeJoy, Robert Jeyaseelan, Dennis Powell, (unknown), Bryan O’Hara, Michael M. Wick, Arnold L. Oronsky, S.S. Kerwar	5
14	Pluronic F 127 liquid sensitizes mice to low doses of Escherichia coli lipopolysaccharide 1992 ·Critical Care Medicine ·Walter C. Pickett, Lawrence W. Torley, Susan Quinn DeJoy, James J. Gibbons, (unknown), Arnold L. Oronsky, S.S. Kerwar	1
15	Fructose-induced fluorescence generation of reductively methylated glycated bovine serum albumin: Evidence for nonenzymatic glycation of Amadori adducts 1991 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Gerardo Suárez, (unknown), Arnold L. Oronsky, Carmen Raventós-Suárez	29
16	Platelet-Activating Factor or a Platelet-Activating Factor Antagonist Decreases Tumor Necrosis Factor- in the Plasma of Mice Treated with Endotoxin 1990 ·The Journal of Infectious Diseases ·(unknown), Andrew S. Katocs, W C Pickett, (unknown), (unknown), Arnold L. Oronsky, S.S. Kerwar	18
17	Studies on the homing of Mycobacterium-sensitized T lymphocytes to the synovium during passive adjuvant arthritis 1990 ·Cellular Immunology ·Susan Quinn DeJoy, (unknown), Arnold L. Oronsky, John B. Zabriskie, S.S. Kerwar	12
18	Antiinflammatory steroid action: Basic and clinical aspects 1990 ·Arthritis & Rheumatism ·Robert P. Schleimer, Henry N. Claman, Arnold L. Oronsky, James S. Goodwin	168
19	Administration of an aldose reductase inhibitor induces a decrease of collagen fluorescence in diabetic rats. 1988 ·Journal of Clinical Investigation ·Guillaume Suárez, Rama Rajaram, Kailash C. Bhuyan, Arnold L. Oronsky, (unknown)	53
20	In vivo chemotaxis (Cx): Effect of pharmacological agents 1973 ·Federation Proceedings ·Martin G. Sanda, Glay Chinea, Arnold L. Oronsky	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact